Agonist | t0.5 | t0.9 | n |
---|---|---|---|
min | |||
R-PIA | 7.9 ± 0.1 | 12.6 ± 0.8 | 3 |
CGS21680 | 14.5 ± 0.5 | 19.5 ± 0.9 | 3 |
CVT-2995 | 17.5 ± 1.2 | 23.2 ± 2.1 | 4 |
WRC0470 | 21.9 ± 0.9 | 27.9 ± 1.4 | 6 |
CVT-3032 | 4.1 ± 0.3 | 9.8 ± 1.4 | 4 |
CVT-3033 | 3.4 ± 0.5 | 8.4 ± 2.2 | 4 |
CVT-3146 | 5.2 ± 0.2 | 11.3 ± 1.1 | 5 |
YT-146 | 17.7 ± 1.0 | 25.8 ± 4.0 | 3 |
CVT-3003 | 3.4 ± 0.1 | 9.2 ± 2.2 | 4 |
CVT-3006 | 16.1 ± 0.1 | 21.8 ± 2.0 | 3 |
CVT-3100 | 5.1 ± 0.6 | 10.1 ± 0.2 | 4 |
CVT-3101 | 16.7 ± 0.5 | 25.6 ± 0.3 | 3 |
CVT-3126 | 8.3 ± 0.4 | 12.6 ± 0.3 | 4 |
CVT-3127 | 14.8 ± 2.1 | 15.0 ± 0.8 | 3 |
CVT-3141 | 14.4 ± 1.9 | 21.3 ± 3.9 | 4 |
CVT-3144 | 13.6 ± 1.3 | 18.9 ± 1.9 | 4 |
HENECA | 28.6 ± 1.1 | 32.8 ± 3.1 | 3 |
Adenosine | 1.6 ± 0.1 | 5.6 ± 0.8 | 11 |
Times (min) to 50 and 90% (t0.5 andt0.9, respectively) reversal of the increases in coronary conductance caused by adenosine and adenosine receptor agonists. Values are the mean ± S.E.M. of single determinations in each of n preparations.